Daniel Gaudet
Impact in
-
- Diabetes, Cardiovascular Risks, and Lipoproteins
-
- Lipid metabolism and disorders
Papers in
- Surgery 164
- Lipoproteins and Cardiovascular Health 142
-
- Lipid metabolism and disorders 133
- Co-authors
- Diane Brisson (108 shared papers)Marie‐Claude Vohl (42 shared papers)Thomas J. Hudson (21 shared papers)Claude Gagné (27 shared papers)Jean‐Pierre Després (31 shared papers)Joel N. Hirschhorn (16 shared papers)David Altshuler (15 shared papers)Patrice Perron (40 shared papers)
- Journals
- Journal of clinical lipidology (48 papers)Atherosclerosis (44 papers)Circulation (23 papers)Journal of the American College of Cardiology (15 papers)Diabetes (14 papers)
- Partner nations
- CanadaUnited StatesNetherlands
In The Last Decade
Daniel Gaudet
408 papers receiving 18.9k citations
Daniel Gaudet's Hit Papers
Peers
Comparison fields: 5 of 164
- Endocrinology, Diabetes and Metabolism 4.2k
- Cardiology and Cardiovascular Medicine 4.7k
- Surgery 7.5k
- Cancer Research 2.1k
- Genetics 2.2k
Countries citing papers authored by Daniel Gaudet
This map shows the geographic impact of Daniel Gaudet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Gaudet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Gaudet more than expected).
Fields of papers citing papers by Daniel Gaudet
This network shows the impact of papers produced by Daniel Gaudet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Gaudet. The network helps show where Daniel Gaudet may publish in the future.
Co-authors
The 25 scholars most cited alongside Daniel Gaudet, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 425 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes Hit paper breakdown → | 2000 | 1311 |
| 2 | Hypertriglyceridemic Waist Hit paper breakdown → | 2000 | 754 |
| 3 | Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial Hit paper breakdown → | 2010 | 694 |
| 4 | PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial Hit paper breakdown → | 2014 | 570 |
| 5 | Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study Hit paper breakdown → | 2012 | 535 |
| 6 | Evinacumab for Homozygous Familial Hypercholesterolemia Hit paper breakdown → | 2020 | 503 |
| 7 | Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial Hit paper breakdown → | 2012 | 463 |
| 8 | Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome Hit paper breakdown → | 2019 | 439 |
| 9 | Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia Hit paper breakdown → | 2015 | 410 |
| 10 | Targeting APOC3 in the Familial Chylomicronemia Syndrome Hit paper breakdown → | 2014 | 389 |
| 11 | 2002 | 358 | |
| 12 | Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease Hit paper breakdown → | 2022 | 351 |
| 13 | 2012 | 308 | |
| 14 | Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance Hit paper breakdown → | 2019 | 306 |
| 15 | 2004 | 236 | |
| 16 | 2012 | 228 | |
| 17 | Evinacumab in Patients with Refractory Hypercholesterolemia Hit paper breakdown → | 2020 | 221 |
| 18 | 2013 | 208 | |
| 19 | Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia Hit paper breakdown → | 2020 | 204 |
| 20 | 2014 | 195 |
About Daniel Gaudet
Daniel Gaudet is a scholar working on Surgery, Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, Molecular Biology and Cancer Research, having authored 425 papers that have together received 19.5k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (142 papers), Lipid metabolism and disorders (133 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (58 papers), Cancer, Lipids, and Metabolism (54 papers), Diabetes and associated disorders (20 papers), Metabolism, Diabetes, and Cancer (19 papers), Peroxisome Proliferator-Activated Receptors (17 papers) and Genetic Associations and Epidemiology (15 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (4.2k citations), Cardiology and Cardiovascular Medicine (4.7k citations), Surgery (7.5k citations), Cancer Research (2.1k citations) and Genetics (2.2k citations). Daniel Gaudet has collaborated with scholars based in Canada, United States and Netherlands. Frequent co-authors include Diane Brisson, Marie‐Claude Vohl, Thomas J. Hudson, Claude Gagné, Jean‐Pierre Després, Joel N. Hirschhorn, David Altshuler, Patrice Perron, Karine Tremblay and G Tremblay. Their work appears in journals such as Journal of clinical lipidology, Atherosclerosis, Circulation, Journal of the American College of Cardiology and Diabetes.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.